Phio Pharmaceuticals Completes Enrollment for PH-762 Trial

Phio Pharmaceuticals ( (PHIO) ) has provided an announcement.

On November 25, 2025, Phio Pharmaceuticals announced the completion of patient enrollment in its Phase 1b clinical trial for PH-762, a siRNA compound targeting skin cancer. The trial, which evaluates safety and tolerability, showed promising results with several patients achieving complete or partial responses, and no dose-limiting toxicities observed. This milestone advances PH-762 as a potential treatment for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma, with pathology results expected in Q1 2026.

The most recent analyst rating on (PHIO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Phio Pharmaceuticals stock, see the PHIO Stock Forecast page.

Spark’s Take on PHIO Stock

According to Spark, TipRanks’ AI Analyst, PHIO is a Neutral.

Phio Pharmaceuticals is struggling financially, with no revenue and consistent losses, significantly impacting its stock score. The technical indicators show mixed signals, with some short-term momentum but bearish long-term trends. The valuation is speculative due to negative earnings. The recent board appointment is a positive corporate event but has limited impact on overall financial health.

To see Spark’s full report on PHIO stock, click here.

More about Phio Pharmaceuticals

Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company specializing in siRNA-based therapeutics. The company focuses on developing its proprietary INTASYL® gene silencing technology for immuno-oncology applications, aiming to enhance immune cell effectiveness against cancer cells. Its lead program, PH-762, targets the PD-1 gene associated with various skin cancers, offering a potential non-surgical treatment option.

Average Trading Volume: 2,824,801

Technical Sentiment Signal: Strong Sell

Current Market Cap: $12.49M

Find detailed analytics on PHIO stock on TipRanks’ Stock Analysis page.